Non-invasive assessment of tumor PD-L1 status with circulating tumor cells.
作者信息
Ulrich Bryan C, Guibert Nicolas
机构信息
Emory School of Medicine, Atlanta, GA, USA.
Thoracic Oncology Department, Larrey Hospital, University Hospital of Toulouse, Toulouse, France.
出版信息
Ann Transl Med. 2018 Nov;6(Suppl 1):S48. doi: 10.21037/atm.2018.10.09.
Abstract
摘要
相似文献
1
Non-invasive assessment of tumor PD-L1 status with circulating tumor cells.利用循环肿瘤细胞对肿瘤程序性死亡受体配体1（PD-L1）状态进行无创评估。
Ann Transl Med. 2018 Nov;6(Suppl 1):S48. doi: 10.21037/atm.2018.10.09.
2
Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer.检测晚期非小细胞肺癌患者循环肿瘤细胞和白细胞中的 PD-L1。
Ann Oncol. 2018 Jan 1;29(1):193-199. doi: 10.1093/annonc/mdx636.
3
A preliminary study for the assessment of PD-L1 and PD-L2 on circulating tumor cells by microfluidic-based chipcytometry.一项基于微流控芯片细胞术评估循环肿瘤细胞上PD-L1和PD-L2的初步研究。
Future Sci OA. 2017 Sep 4;3(4):FSO244. doi: 10.4155/fsoa-2017-0079. eCollection 2017 Nov.
4
Correlation between High PD-L1 and EMT/Invasive Genes Expression and Reduced Recurrence-Free Survival in Blood-Circulating Tumor Cells from Patients with Non-Muscle-Invasive Bladder Cancer.非肌层浸润性膀胱癌患者循环肿瘤细胞中高PD-L1与EMT/侵袭基因表达的相关性及无复发生存率降低
Cancers (Basel). 2021 Nov 28;13(23):5989. doi: 10.3390/cancers13235989.
5
PD-L1 and epithelial-mesenchymal transition in circulating tumor cells from non-small cell lung cancer patients: A molecular shield to evade immune system非小细胞肺癌患者循环肿瘤细胞中的程序性死亡受体配体1（PD-L1）与上皮-间质转化：一种逃避免疫系统的分子屏障
Oncoimmunology. 2017 Apr 20;6(12):e1315488. doi: 10.1080/2162402X.2017.1315488. eCollection 2017.
6
Assessment of PD-L1 Expression on Circulating Tumor Cells for Predicting Clinical Outcomes in Patients with Cancer Receiving PD-1/PD-L1 Blockade Therapies.评估接受 PD-1/PD-L1 阻断治疗的癌症患者循环肿瘤细胞中 PD-L1 表达水平预测临床结局。
Oncologist. 2021 Dec;26(12):e2227-e2238. doi: 10.1002/onco.13981. Epub 2021 Sep 28.
7
Clinical Significance of PD-L1 Status in Circulating Tumor Cells for Cancer Management during Immunotherapy.循环肿瘤细胞中PD-L1状态在免疫治疗期间癌症管理中的临床意义。
Biomedicines. 2023 Jun 20;11(6):1768. doi: 10.3390/biomedicines11061768.
8
PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab.纳武利尤单抗治疗晚期非小细胞肺癌患者循环肿瘤细胞中 PD-L1 的表达。
Lung Cancer. 2018 Jun;120:108-112. doi: 10.1016/j.lungcan.2018.04.001. Epub 2018 Apr 3.
9
Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer.评价转移性肺癌中涡旋分离循环肿瘤细胞的 PD-L1 表达。
Sci Rep. 2018 Feb 7;8(1):2592. doi: 10.1038/s41598-018-19245-w.
10
Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients.肌肉浸润性和转移性膀胱癌患者循环肿瘤细胞（CTC）的程序性死亡配体1（PD-L1）特征分析
BMC Cancer. 2016 Sep 22;16(1):744. doi: 10.1186/s12885-016-2758-3.
引用本文的文献
1
Immunotherapy for Limited-Stage Small Cell Lung Cancer: Innovative Treatments and Future Perspectives.局限期小细胞肺癌的免疫治疗：创新疗法与未来展望
Cancer Control. 2025 Jan-Dec;32:10732748251334434. doi: 10.1177/10732748251334434. Epub 2025 Apr 14.
2
Potential predictors of immunotherapy in small cell lung cancer.小细胞肺癌免疫治疗的潜在预测因子。
Pathol Oncol Res. 2023 May 3;29:1611086. doi: 10.3389/pore.2023.1611086. eCollection 2023.
3
Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.肿瘤突变负担作为度伐利尤单抗和/或替西木单抗治疗复发性或转移性头颈部鳞状细胞癌患者生存的预测指标。
Clin Cancer Res. 2023 Jun 1;29(11):2066-2074. doi: 10.1158/1078-0432.CCR-22-2765.
4
Circulating CD81-expressing extracellular vesicles as biomarkers of response for immune-checkpoint inhibitors in advanced NSCLC.循环 CD81 表达的细胞外囊泡作为晚期 NSCLC 免疫检查点抑制剂反应的生物标志物。
Front Immunol. 2022 Sep 20;13:987639. doi: 10.3389/fimmu.2022.987639. eCollection 2022.
5
Comprehensive Genomic Profiling Reveals Clinical Associations in Response to Immune Therapy in Head and Neck Cancer.综合基因组分析揭示头颈部癌免疫治疗反应中的临床关联。
Cancers (Basel). 2022 Jul 18;14(14):3476. doi: 10.3390/cancers14143476.
6
Relationship between Tumor Mutational Burden, PD-L1, Patient Characteristics, and Response to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma.头颈部鳞状细胞癌中肿瘤突变负荷、程序性死亡受体配体1、患者特征与免疫检查点抑制剂反应之间的关系
Cancers (Basel). 2021 Nov 16;13(22):5733. doi: 10.3390/cancers13225733.
7
A narrative review of current and potential prognostic biomarkers for immunotherapy in small-cell lung cancer.小细胞肺癌免疫治疗的当前及潜在预后生物标志物的叙述性综述。
Ann Transl Med. 2021 May;9(9):809. doi: 10.21037/atm-21-68.
8
Extracellular Vesicles as Biomarkers in Cancer Immunotherapy.细胞外囊泡作为癌症免疫治疗中的生物标志物
Cancers (Basel). 2020 Sep 30;12(10):2825. doi: 10.3390/cancers12102825.
9
PD-L1 Expression on Circulating Tumor Cells May Be Predictive of Response to Pembrolizumab in Advanced Melanoma: Results from a Pilot Study.循环肿瘤细胞上的 PD-L1 表达可能对晚期黑色素瘤患者接受派姆单抗治疗的反应具有预测性：一项初步研究的结果。
Oncologist. 2020 Mar;25(3):e520-e527. doi: 10.1634/theoncologist.2019-0557. Epub 2019 Dec 5.
10
Current and future applications of liquid biopsy in nonsmall cell lung cancer from early to advanced stages.液体活检在非小细胞肺癌从早期到晚期的当前和未来应用。
Eur Respir Rev. 2020 Feb 12;29(155). doi: 10.1183/16000617.0052-2019. Print 2020 Mar 31.
本文引用的文献
1
Programmed Cell Death 1 (PD-1) Ligand (PD-L1) Expression in Solid Tumors As a Predictive Biomarker of Benefit From PD-1/PD-L1 Axis Inhibitors: A Systematic Review and Meta-Analysis.实体瘤中程序性细胞死亡蛋白1（PD-1）配体（PD-L1）的表达作为从PD-1/PD-L1轴抑制剂中获益的预测生物标志物：一项系统评价和荟萃分析
JCO Precis Oncol. 2017 Nov;1:1-15. doi: 10.1200/PO.16.00030.
2
Immunotherapy efficacy and gender: discovery in precision medicine.免疫疗法疗效与性别：精准医学中的发现
Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S211-S213. doi: 10.21037/tlcr.2018.08.05.
3
Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis.癌症免疫疗法的疗效与患者性别：系统评价和荟萃分析。
Lancet Oncol. 2018 Jun;19(6):737-746. doi: 10.1016/S1470-2045(18)30261-4. Epub 2018 May 16.
4
PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab.纳武利尤单抗治疗晚期非小细胞肺癌患者循环肿瘤细胞中 PD-L1 的表达。
Lung Cancer. 2018 Jun;120:108-112. doi: 10.1016/j.lungcan.2018.04.001. Epub 2018 Apr 3.
5
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.纳武利尤单抗联合伊匹单抗治疗高肿瘤突变负荷肺癌。
N Engl J Med. 2018 May 31;378(22):2093-2104. doi: 10.1056/NEJMoa1801946. Epub 2018 Apr 16.
6
Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer.评价转移性肺癌中涡旋分离循环肿瘤细胞的 PD-L1 表达。
Sci Rep. 2018 Feb 7;8(1):2592. doi: 10.1038/s41598-018-19245-w.
7
Evaluation of PD-L1/PD-1 on circulating tumor cells in patients with advanced non-small cell lung cancer.晚期非小细胞肺癌患者循环肿瘤细胞上PD-L1/PD-1的评估
Ther Adv Med Oncol. 2018 Jan 15;10:1758834017750121. doi: 10.1177/1758834017750121. eCollection 2018.
8
Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer.检测晚期非小细胞肺癌患者循环肿瘤细胞和白细胞中的 PD-L1。
Ann Oncol. 2018 Jan 1;29(1):193-199. doi: 10.1093/annonc/mdx636.
9
Cell-Free DNA in Oncology: Gearing up for Clinic.肿瘤游离 DNA：为临床应用做好准备。
Ann Lab Med. 2018 Jan;38(1):1-8. doi: 10.3343/alm.2018.38.1.1.
10
PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project.PD-L1 免疫组织化学检测在肺癌中的应用：蓝图 PD-L1 IHC 检测比较项目第一阶段的结果。
J Thorac Oncol. 2017 Feb;12(2):208-222. doi: 10.1016/j.jtho.2016.11.2228. Epub 2016 Nov 29.
Zotero 插件